IART Stock Recent News
IART LATEST HEADLINES
In spite of facing foreign exchange fluctuations across its non-U.S. business, Integra (IART) is successfully broadening its international footprint.
Integra LifeSciences Holdings Corporation faces uncertainties and challenges due to the ongoing issues at its Boston manufacturing facility. The company's financials have been impacted by this, despite reasonable organic growth in the rest of its core portfolio. The stock's negative sentiment, compressed valuations, and lack of secondary catalysts suggest limited upside potential.
In CSS, Integra (IART) registers strong growth owing to high single-digit growth in Advanced Energy and mid-single-digit growth in CSF management during Q2.
Integra LifeSciences (IART) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.82 per share a year ago.
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integra's (IART) Codman Bactiseal EVD lowers financial burdens and guarantees a safe clinical outcome in patients with aSAH-related hydrocephalus.
PRINCETON, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2023 financial results on Thursday, July 27, 2023, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
Integra (IART) announces the completion of patient enrollment in the DuraSorb IDE clinical study.
NGVT, IART and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2023.
Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.